

LIST OF CONTENTS

NUMBER 1

<i>Announcement</i>	1
<i>International Cancer News</i>	3
<i>Editorial</i>	
The prognostic value of cathepsin D in breast cancer. A long road to the clinic <i>H. Rochefort</i>	7
<i>Points of View</i>	
The breast screening controversy <i>M. Baum</i>	9
What do we know on variables influencing clinical decision-making in elderly cancer patients? <i>S. Monfardini</i>	12
<i>Special Paper</i>	
Cathepsin D and breast cancer <i>B.R. Westley and F.E.B. May</i>	15
<i>Reviews</i>	
Palliative endoscopic therapy of rectal carcinoma <i>M. Dohmoto, M. Hünerbein and P.M. Schlag</i>	25
Role of oxygen free radicals in cancer development <i>D. Dreher and A.F. Junod</i>	30
<i>Meeting Highlight</i>	
On the threshold of success? Report on ECCO8, 29 October–2 November 1995, Paris, France <i>D.C. Purves and I.R. Hart</i>	39
<i>Clinical Oncology</i>	
Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes? <i>F. Perrone, C. Carlomagno, R. Lauria, M. De Laurentiis, A. Morabito, L. Panico, G. Pettinato, G. Petrella, C. Gallo, A.R. Bianco and S. De Placido</i>	41
A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines <i>G. Fountzilas, A. Athanassiades, T. Giannakakis, D. Bafaloukos, K. Karakousis, N. Dombros, P. Kosmidis and D. Skarlos</i>	47

A randomised study comparing granulocyte-colony stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of haematological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy <i>F. Sanchiz and A. Milla</i>	52
An economic model to assess the savings from a clinical application of haematopoietic growth factors <i>C.A. Uyl-de Groot, E. Vellenga and F.F.H. Rutten</i>	57
The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer <i>A. Webb, P. Scott-Mackie, D. Cunningham, A. Norman, J. Andreyev, M. O'Brien and J. Bensted</i>	63
A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer <i>C. Cotto, J. Berille, P.J. Souquet, R. Riou, B. Croisile, F. Turjman, B. Giroux, J. Brune and V. Trillet-Lenoir</i>	69
The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853 <i>F.C. da Silva, S.D. Fossa, N.K. Aaronson, S. Serbouti, L. Denis, J. Casselman, P. Whelan, J. Hetherington, C. Fava, B. Richards, M.R.G. Robinson and the members of the EORTC Genitourinary Tract Cancer Cooperative Group</i>	72
Helping cancer patients disclose their concerns <i>P. Maguire, A. Faulkner, K. Booth, C. Elliott and V. Hillier</i>	78
An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens <i>A. Martoni, B. Angelelli, M. Guaraldi, E. Stocchi and F. Pannuti</i>	82
<i>MDR1</i> gene expression: evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas <i>U. Stein, R.H. Shoemaker and P.M. Schlag</i>	86
 <i>Paediatric Oncology</i>	
Radiolabelled mIBG in the treatment of neuroblastoma <i>M.N. Gaze and T.E. Wheldon</i>	93
Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation <i>J. Pihkala, U.M. Saarinen, U. Lundström, K. Virtanen, K. Virkola, M.A. Siimes and E. Pesonen</i>	97
 <i>Cancer Epidemiology and Prevention</i>	
Quality of prostate cancer data in the Cancer Registry of Norway <i>S. Harvei, S. Tretli and F. Langmark</i>	104
Cancer of the prostate in Norway 1957–1991—a descriptive study <i>S. Harvei, S. Tretli and F. Langmark</i>	111
Does age at the last birth affect breast cancer risk? <i>C.-C. Hsieh, H.-W. Chan, M. Lambe, A. Ekbom, H.-O. Adami and D. Trichopoulos</i>	118

Experimental Oncology

Ectopic vasopressin expression in MMTV- <i>v-Ha-ras</i> transgenic mice delays the onset of mammary tumorigenesis <i>K.-F. Chooi, D.A. Carter and D. Murphy</i>	122
Multiple drug resistance-related messenger RNA expression in archival formalin-fixed paraffin-embedded human breast tumour tissue <i>L. O'Driscoll, S. Kennedy, E. McDermott, P. Kelehan and M. Clynes</i>	128
Anti-oestrogen stimulation of ERBB2 ectodomain shedding from BT-474 human breast cancer cells with <i>ERBB2</i> gene amplification <i>A.M. Warri, J. J. Isola and P.L. Härkönen</i>	134
Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells <i>B. Passlick, K. Pantel, B. Kubuschok, M. Angstwurm, A. Neher, O. Thetter, L. Schweiberer and J.R. Izbicki</i>	141
Inhibitions of protein kinase C and proto-oncogene expressions in NIH 3T3 cells by apigenin <i>Ying-Tang Huang, Min-Liang Kuo, Jer-Yuh Liu, Su-Yu Huang and Jen-Kun Lin</i>	146
The antimetabolite tiazofurin (TR) inhibits glycoconjugate biosynthesis and invasiveness of tumour cells <i>J. Timár, J. Tóvári, G. Pogány, A. Ladányi, S. Paku, E. Rásó, J. Bocsi, A. Jenei and K. Lapis</i>	152
SR8—the establishment and characterisation of a new ovarian carcinoma cell line and xenograft model <i>X. Han, A.J. Papadopoulos, T.A. Jones, D. Sheer and K.S. Raju</i>	160
Immunostaining of human melanomas by a monoclonal antibody to B700 mouse melanoma antigen <i>X. Xu, N. Azumi, H.G. Skelton, V.J. Hearing and D.M. Gersten</i>	168

Letters

Adjuvant tamoxifen: 5 year control of dormant disease? <i>O. Merimsky, M. Inbar, F. Kovner and S. Chaichik</i>	174
High frequency of urothelial cancers in patients with kidney transplantations for end-stage analgesic nephropathy <i>C. Bokemeyer, W.F. Thon, T. Brunkhorst, M.A. Kuczyk, R. Pichlmayr and V. Kliem</i>	175
Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study <i>G. Gardin, C. Barone, O. Nascimben, G. Ianniello, F. Sturba, A. Contu, P. Pronzato and R. Rosso</i>	176
MSH2 sequence variations and inherited colorectal cancer susceptibility <i>N.J. Froggatt, J.A. Joyce, D.G.R. Evans, P.W. Lunt, D.J. Koch, B.J. Ponder and E.R. Maher</i>	178
Chemotherapy with doxorubicin, etoposide and cyclophosphamide (DEC) in ovarian cancer persistent after platinum-based treatment <i>G. Zanetta, S. Lo Monaco, A. Gabriele, D. Miceli and C. Mangioni</i>	178
Upper age limit for cervical cancer screening <i>S. Cecchini, A. Iossa and S. Ciatto</i>	180

Dacarbazine, vincristine, bleomycin and lomustine plus natural interferon-alpha for metastatic melanoma <i>U. Reinhold, Th. Bruske and H.W. Kreysel</i>	180
Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group <i>V. Urosevic, Ph. Chollet, A. Adenis, J. Chauvergne, P. Fargeot, H. Roche, P. Kerbrat, M.A. Lentz, P. Fumoleau and B. Chevallier</i>	181
Octreotide treatment of chemotherapy-induced diarrhoea <i>P. Ginopoulos, Th. Papagiannis, Ch. Safridi, F. Karvelas, K. Spyropoulos, Th. Papadas and Ch. Gogos</i>	182
<i>Corrections</i>	185
<i>Calendar of Forthcoming Meetings</i>	187
Information for Authors	I
 NUMBER 2	
<i>International Cancer News</i>	195
 <i>Editorial</i>	
Radon and childhood cancers <i>L. Parker and A.W. Craft</i>	201
 <i>Point of View</i>	
High-dose chemotherapy for breast cancer <i>R.C.F. Leonard</i>	205
 <i>Special Paper</i>	
Current and future trends in the multidisciplinary approach for high-risk breast cancer. The experience of the Milan Cancer Institute <i>G. Bonadonna</i>	209
 <i>Clinical Oncology</i>	
Expression of p53 protein as a prognostic factor in patients with gastric cancer <i>M. Victorzon, S. Nordling, C. Haglund, J. Lundin and P.J. Roberts</i>	215
Prognostic value of serum alpha-1-antitrypsin in hepatocellular carcinoma <i>M. Pirisi, C. Fabris, G. Soardo, P. Toniutto, D. Vitulli and E. Bartoli</i>	221

Evaluation of antitumour effects of docetaxel (Taxotere®) on human gastric cancers <i>in vitro</i> and <i>in vivo</i> <i>M. Tanaka, T. Obata and T. Sasaki</i>	226
Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients <i>F. Revillion, M. Hebbar, J. Bonneterre and J.P. Peyrat</i>	231
Postoperative adjuvant randomised trial comparing chemo-endocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemo-endocrine Therapy for Breast Cancer (ACETBC) of Japan <i>T. Morimoto, M. Ogawa, K. Orita, K. Sugimachi, T. Toge, K. Dohi, Y. Nomura, Y. Monden and N. Ogawa</i>	235
Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study <i>U. Gatzemeier, F.A. Shepherd, T. Le Chevalier, P. Weynants, B. Cottier, H.J.M. Groen, R. Rosso, K. Mattson, H. Cortes-Funes, M. Tonato, R.L. Burkes, M. Gottfried and M. Voi</i>	243
Concurrent radiotherapy and continuous ambulatory infusion 5-fluorouracil in advanced head and neck cancer <i>I.N. Olver, P.G. Hughes, J.G. Smith, K. Narayan and J.F. Bishop</i>	249
Well-differentiated papillary mesothelioma of the peritoneum: a separate entity <i>K. Hoekman, G. Tognon, E.K.J. Risse, C.A. Bloemsa and J.B. Vermorken</i>	255
Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome <i>G. Scambia, P. Benedetti Panici, E. Foti, G. Ferrandina, F.P.G. Leone, M. Marciano and S. Mancuso</i>	259
Identification of lymph node metastases by use of polymerase chain reaction (PCR) in melanoma patients <i>M. Schwürzer-Voit, T.M. Probstle and W. Sterry</i>	264
The importance of a multidisciplinary group in the treatment of soft tissue sarcomas <i>T. Wiklund, R. Huuhtanen, C. Blomqvist, E. Tukiainen, M. Virolainen, P. Virkkunen, S. Asko-Seljavaara, J.M. Björkenheim and I. Elomaa</i>	269
Spiritual healing among Norwegian hospitalised cancer patients and patients' religious needs and preferences of pastoral services <i>T. Risberg, E. Wist, S. Kaasa, E. Lund and J. Norum</i>	274

Paediatric Oncology

Radon in Devon and Cornwall and paediatric malignancies <i>R. Thorne, N.K. Foreman and M.G. Mott</i>	282
Small influence of parental educational level on the survival of children with leukaemia in The Netherlands between 1973 and 1979 <i>J.W.W. Coebergh, A. van der Does-van den Berg, W.C.J. Hop, F. van Weerden, J.A. Rammeloo, H.A. van Steensel, E.R. van Wering and W.A. Kamps</i>	286

Information about diagnosis and prognosis related to anxiety and depression in children with cancer aged 8–16 years	290
<i>B.F. Last and A.M.H. van Veldhuizen</i>	

Cancer Epidemiology and Prevention

Survival for colon and rectal cancer in a population-based cancer registry	295
<i>L. Roncucci, R. Fante, L. Losi, C. Di Gregorio, A. Micheli, P. Benatti, N. Madenis, D. Ganazzi, M.T. Cassinadri, P. Lauriola and M. Ponz de Leon</i>	
The role of reproductive and menstrual factors in cancer of the breast before and after menopause	303
<i>R. Talamini, S. Franceschi, C. La Vecchia, E. Negri, L. Borsa, M. Montella, F. Falcini, E. Conti and C. Rossi</i>	

Experimental Oncology

Lack of effect of corticosteroids and tamoxifen on suramin protein binding and <i>in vitro</i> activity	311
<i>D.L. Driscoll, R.W. Steinkampf, L.J. Paradiso, C.D. Kowal and W.D. Klohs</i>	
Red blood cell polyamines, anaemia and tumour growth in the rat	316
<i>V. Quemener, J.Y. Bansard, M. Delamaire, S. Roth, R. Havouis, D. Desury and J.-Ph. Moulinoux</i>	
Reversion of UVC-induced tumorigenic human hybrid cells to the non-tumorigenic phenotype	322
<i>C. Sun, R. J. Antonionio and J. L. Redpath</i>	
Photodynamic effects of 5-aminolevulinic acid-induced porphyrin on human bladder carcinoma cells <i>in vitro</i>	328
<i>R. Riesenberger, C. Fuchs and M. Kriegmair</i>	
Frequent <i>TP53</i> gene alterations (mutation, allelic loss, nuclear accumulation) in primary non-small cell lung Cancer	335
<i>R. Shipman, P. Schraml, M. Colombi, G. Raefle, P. Dalquen and C. Ludwig</i>	
Effect of tyrphostin combined with a substance P related antagonist on small cell lung cancer cell growth <i>in vitro</i>	342
<i>M.J. Seckl and E. Rozengurt</i>	
Newly established MST-1 tumour cell line and tumour-infiltrating lymphocyte culture from a patient with soft tissue melanoma (clear cell sarcoma) and their potential applications to patient immunotherapy	346
<i>S.-K. Liao, Y.-P. Perng, L.-A. Lee, K.S.S. Chang, G.-M. Lai, E. Wong and Y.-S. Ho</i>	
Correlations of Ki-67 and PCNA to DNA ploidy, S-phase fraction and survival in uveal melanoma	357
<i>M. Karlsson, B. Boeryd, J. Carstensen, B. Frånlund, B. Gustafsson, B. Kågedal, X.-F. Sun and S. Wingren</i>	

Short Communications

Epithelial tumour cells in bone marrow of patients with pancreatic carcinoma detected by immunocytochemical staining	363
<i>S. Thorban, J.D. Roder, K. Pantel and J.R. Sievert</i>	

Retinoic acid concentrations in patients with squamous cell carcinoma of the head and neck <i>P. Wahlberg and G. Fex</i>	366
<i>Letters</i>	
5-Fluorouracil cardiotoxicity: a unique mechanism for ischaemic cardiopathy and cardiac failure? <i>T. Lieutaud, E. Brain, D. Golgran-Toledano, F. Vincent, E. Cvitkovic, B. Leclercq and B. Escudier</i>	368
Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta <i>P. Beuzeboc, J.-Y. Pierga, D. Stoppa-Lyonnet, M.C. Etienne, G. Milano and P. Poullart</i>	369
Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy. A retrospective study of 63 cases <i>L. Cany, C. Toulouse, A. Ravaud, M. Durand and L. Mauriac</i>	370
Studies of HLA-A and DR locus deletions in human liver cancer cell lines by PCR <i>Qing Li, S. H. Chan and E. C. Ren</i>	371
Adenocarcinoma of the eccrine sweat gland: response to both combination chemotherapy and local field irradiation <i>W.C. Mertens, D.T. Shum and J.A. Gilchrist</i>	372
Chemotherapy-induced onycholysis <i>A. Makris, P. Mortimer and T.J. Powles</i>	374
Prevention of second primary tumours with a second generation retinoid in squamous cell carcinoma of oral cavity and oropharynx: long term follow-up <i>M. Bolla, A. Laplanche, R. Lefur, J. Ton Van, C. Domenge, J.-L. Lefebvre and B. Lubinski for the French Study Group on Head and Neck Tumour (GETTEC) France</i>	375
"It feels better"—measuring clinical benefit <i>D.D. Von Hoff</i>	376
<i>Calendar of Forthcoming Meetings</i>	379
Information for Authors	I
 NUMBER 3	
<i>International Cancer News</i>	387
 <i>Editorials</i>	
Cancer genetics clinics <i>D.G.R. Evans, J. Cuzick and A. Howell</i>	391

New aromatase inhibitors: more selectivity, less toxicity, unfortunately, the same activity <i>M. Castiglione-Gertsch</i>	393
--	-----

Point of View

Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression <i>R.T.D. Oliver, J. Tobias and C. Gallagher</i>	396
--	-----

Special Paper

Cancer genetics clinics: target population and consultees' expectations <i>C. Julian-Reynier, F. Eisinger, F. Chabal, Y. Aurran, C. Noguès, P. Venmin, Y.-J. Bignon, M. Machelard-Roumagnac, C. Maugard-Louboutin, D. Serin, S. Versini, M. Mercuri and H. Sobol</i>	398
---	-----

Clinical Oncology

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer <i>W. Jonat, A. Howell, C. Blomqvist, W. Eiermann, G. Winblad, C. Tyrrell, L. Mauriac, H. Roche, S. Lundgren, R. Hellmund and M. Azab on behalf of the ARIMIDEX Study Group</i>	404
Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor- α protein expression in human breast cancer <i>R.A. McClelland, J.M.W. Gee, A.B. Francis, J.F.R. Robertson, R.W. Blamey, A.E. Wakeling and R.I. Nicholson</i>	413
Prognosis of patients with breast cancers up to 1 cm in diameter <i>I.S. Fentiman, D. Hyland, M.A. Chaudary and W.M. Gregory</i>	417
Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic Co-operative Oncology Group study <i>D.V. Skarlos, G. Aravantinos, P. Kosmidis, N. Pavlidis, K. Gennatas, M. Beer, N. Mylonakis, P. Makrantonakis, G. Klouvas, S. Karpathios, H. Linardou, C. Konstantaras and G. Fountzilas</i>	421
Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer <i>E. Roca, E. Pennella, M. Sardi, S. Carraro, M. Barugel, C. Milano, A. Fiorini, R. Giglio, G. Gonzalez, R. Kneitschel, E. Aman, A. Jarentchuk, C. Blajman, J. Nadal, M.T. Santarelli and A. Navigante</i>	429
Prognostic value of resection-line involvement in patients undergoing curative resections for gastric cancer <i>I. Songun, J.J. Bonenkamp, J. Hermans, J.H.J.M. van Krieken, C.J.H. van de Velde and Co-operating Investigators of the Dutch Gastric Cancer Trial</i>	433
Long-term follow-up of a randomised trial of combined chemoradiotherapy induction treatment, with and without maintenance chemotherapy in patients with small cell carcinoma of the lung <i>J.M. Beith, S.J. Clarke, R.L. Woods, D.R. Bell and J.A. Levi</i>	438

Superficial bladder cancer: study of the proliferative nuclear fraction as a prognostic factor <i>E. Blasco-Olaetxea, L. Belloso and J. Garcia-Tamayo</i>	444
Tumour necrosis factor (TNF) soluble receptors in malignant melanoma: correlation with soluble ICAM-1 levels <i>J. Viac, C. Vincent, S. Palacio, D. Schmitt and A. Claudy</i>	447
Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? <i>A.T.M. van Holten-Verzantvoort, J. Hermans, L.V.A.M. Beex, G. Blijham, F.J. Cleton, B.C.F. van Eck-Smit, H.P. Sleeboom and S.E. Papapoulos</i>	450
Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French Cancer Centre multicentric study <i>A. Iliadis, M.-C. Launay-Iliadis, C. Lucas, R. Fety, F. Lokiec, B. Tranchand and G. Milano</i>	455

Paediatric Oncology

The role of bone scintigraphy in the follow-up of osteogenic sarcoma <i>D. Körholz, I. Wirtz, H. Vosberg, W. Rütger, H. Jürgens and U. Göbel</i>	461
Renal function after unilateral nephrectomy for Wilms' tumour: the influence of radiation therapy <i>S.S.N. de Graaf, H. van Gent, W.Ch.C. Reitsma-Bierens, W.H.J. van Luyk, W.V. Dolsma and A. Postma</i>	465

Cancer Epidemiology and Prevention

The follicular non-Hodgkin's lymphomas—I. The possibility of cure <i>J.W. Denham, E. Denham, K.B. Dear and G.V. Hudson</i>	470
The follicular non-Hodgkin's lymphomas—II. Prognostic factors: what do they mean? <i>J.W. Denham, E. Denham, K.B. Dear and G.V. Hudson</i>	480

Experimental Oncology

C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas <i>J. Elnatan, H.-S. Goh and D.R. Smith</i>	491
Anti-idiotypic response to antigrowth factor receptor monoclonal antibodies <i>E. Tosi, O. Valota, S. Canevari, E. Adobati, P. Casalini, P. Perez and M.I. Colnaghi</i>	498
Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB <i>E.A.M. Fleer, D. Berkovic, U. Grunwald and W. Hiddemann</i>	506
TTF-1 gene expression in human lung tumours <i>D. Fabbro, C. Di Loreto, O. Stamerra, C. Alberto Beltrami, R. Lonigro and G. Damante</i>	512

Expression of FGFR2 BEK and K-SAM mRNA variants in normal and malignant human breast <i>Y.A. Luqmani, G.S. Bansal, C. Mortimer, L. Buluwela and R.C. Coombes</i>	518
Intracellular localisation of suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by quantitative autoradiography <i>S. Baghdiguian, J.L. Boudier, J.A. Boudier and J. Fantini</i>	525
Transfection of wild-type TP53 induces differentiation in human gingival carcinoma cells <i>R. Takahashi, T. Inagaki, S. Matsuwari, M. Fujioka, S. Maeda, N. Ijuhin, H. Haga, T. Koh, K. Shimada and H. Saya</i>	533
Effect of intracellular acidity and ionomycin on apoptosis in HL-60 cells <i>H.J. Park, C.M. Makepeace, J.C. Lyons and C.W. Song</i>	540

Short Communications

Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer <i>U. Klaassen, H. Wilke, D. Strumberg, W. Eberhardt, M. Korn and S. Seeber</i>	547
Enhanced effects of bleomycin on pulmonary function disturbances in patients with decreased renal function due to cisplatin <i>S. Sleijfer, T.W. van der Mark, H. Schraffordt Koops and N.H. Mulder</i>	550

Letters

Autologous bone marrow transplantation for uterine sarcoma. Case report <i>F. Recchia, L. Ginaldi, S. Discepoli, M. De Martinis, F. Coloni and D. Quaglino</i>	553
Skin lesions and G-CSF in patients with malignant diseases. Malignancy or cutaneous side-effect? <i>A. Loraas, S.D. Fosså, S. Franzen, G. Sæter and L. Rode</i>	554
Herpesvirus-like DNA sequences selectively cluster with body cavity-based lymphomas throughout the spectrum of AIDS-related lymphomatous effusions <i>A. Carbone, U. Tirelli, A. Gloghini, C. Pastore, E. Vaccher and G. Gaidano</i>	555
Magnesium supplements with cisplatin chemotherapy <i>F.J. Lofts, T.R.J. Evans, R. Wastnage and J.L. Mansi</i>	556

Calendar of Forthcoming Meetings

559

NUMBER 4

<i>International Cancer News</i>	567
<i>Editorials</i>	
Significant trends in cancer in the elderly <i>J.W.W. Coebergh</i>	569
Chemotherapy for ovarian germ cell tumours <i>M. Kaufmann and G.v. Minckwitz</i>	572
<i>Point of View</i>	
Drug evaluation and approval in the European Community <i>M. Marty</i>	574
<i>Special Paper</i>	
New endocrine therapies for breast cancer <i>A. Howell, S. Downey and E. Anderson</i>	576
<i>Review</i>	
Magnetic resonance imaging: present position and future prospects <i>W.L. Curati and G.M. Bydder</i>	589
<i>Clinical Oncology</i>	
Chemotherapy for ovarian germ cell tumours <i>M. Bower, K. Fife, L. Holden, F.J. Paradinas, G.J.S. Rustin and E.S. Newlands</i>	593
Mutant p53 protein as a predictor of survival in endometrial carcinoma <i>P. Strang, B. Nordström, S. Nilsson, R. Bergström and B. Tribukait</i>	598
Reproducibility of histological diagnosis of breast lesions: results of a panel in Italy <i>D. Palli, M. Galli, S. Bianchi, G. Bussolati, S. Di Palma, V. Eusebi, M. Gambacorta and M. Rosselli Del Turco</i>	603
Inadequacy of iridium implant as sole radiation treatment for operable breast cancer <i>I.S. Fentiman, C. Poole, D. Tong, P.J. Winter, W.M. Gregory, H.M.O. Mayles, P. Turner, M.A. Chaudary and R.D. Rubens</i>	608
An image analysis study of DNA content in early colorectal cancer <i>E.W. Kay, H.E. Mulcahy, B. Curran, D.P. O'Donoghue and M. Leader</i>	612
Isolated axillary recurrences after conservative treatment of breast cancer <i>C. Renolleau, P. Merviel, K.B. Clough, B. Asselain, F. Campana and J.C. Durand</i>	617
The management of retroperitoneal soft tissue sarcomas <i>M.P. Jenkins, J.C. Alvaranga and J.M. Thomas</i>	622

Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia <i>K. Jung, M. Lein, S. Weiss, D. Schnorr, W. Henke and S. Loening</i>	627
Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF <i>P.A. Ford, S.G. Arbuck, C. Minniti, L.L. Miller, D. DeMaria and P.J. O'Dwyer</i>	631
Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55 900) in patients with recurrent malignant gliomas <i>G. Straghiotto, F. Vega, P. Stasiecki, P. Gropp, M. Poisson and J.-Y. Delattre</i>	636

Paediatric Oncology

Commentary Multidrug resistance reversal in childhood malignancies—potential for a real step forward? <i>C.R. Pinkerton</i>	641
N-MYC amplification, loss of heterozygosity on the short arm of chromosome 1 and DNA ploidy in retinoblastoma <i>F. Doz, M. Peter, G. Schleiermacher, P. Vielh, P. Validire, M. Putterman, V. Blanquet, L. Desjardins, J.-L. Dufier, J.-M. Zucker, V. Mosseri, G. Thomas, H. Magdelénat and O. Delattre</i>	645
Letter Kaposi's sarcoma in children with AIDS in Europe and the United States <i>D. Serraino and S. Franceschi</i>	650

Cancer Epidemiology and Prevention

Worldwide trends in cancer mortality in the elderly, 1955–1992 <i>F. Levi, C. La Vecchia, F. Lucchini and E. Negri</i>	652
Dietary risk factors for renal cell carcinoma in Denmark <i>A. Møllegaard, J.K. McLaughlin, K. Overvad and J.H. Olsen</i>	673
Multiple primary cancers and estimation of the incidence rates and trends <i>K. Filali, G. Hédelin, P. Schaffer, J. Estève, P. Arveux, C. Bouchardy, C. Exbrayat, J. Faivre, F. Lévi, J. Macé-Lesech, D. Pontier and J. Torhorst</i>	683

Experimental Oncology

Direct gene transfer of a plasmid carrying the herpes simplex virus-thymidine kinase gene (HSV-TK) in transplanted murine melanoma: <i>in vivo</i> study <i>C. Soubrane, R. Mouawad, O. Rixe, V. Calvez, A. Ghomari, O. Verola, M. Weil and D. Khayat</i>	691
Androgen-like and anti-androgen-like effects of antiprogestins in human mammary cancer cells <i>R. Hackenberg, K. Hannig, S. Beck, P. Schmidt-Rhode, A. Scholz and K.-D. Schulz</i>	696
<i>In vitro</i> anti-proliferative and anti-invasive role of amino-terminal fragment of urokinase-type plasminogen activator on 8701-BC breast cancer cells <i>C. Luparello and M. Del Rosso</i>	702
From amsacrine to DACA (N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives <i>G.J. Finlay, J.-F. Riou and B.C. Baguley</i>	708

Characterisation of platelet aggregation induced by PC-3 human prostate adenocarcinoma cells and inhibited by venom peptides, trigramin and rhodostomin <i>M.W. Swaim, H.-S. Chiang and T.-F. Huang</i>	715
Application of competition theory to tumour growth: implications for tumour biology and treatment <i>R.A. Gatenby</i>	722

Short Communications

The invisible colours of melanoma. A telespectrophotometric diagnostic approach on pigmented skin lesions <i>A. Bono, S. Tomatis, C. Bartoli, N. Cascinelli, C. Clemente, C. Cupeta and R. Marchesini</i>	727
Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma <i>M. Guida, A. Latorre, A. Mastria and M. De Lena</i>	730

Letters

Increased risk of malignancy for patients with chronic granulomatous disease and its possible link to the pathogenesis of cancer <i>E.A.M. Weel, W.K. Redekop and R.S. Weening</i>	734
Home therapy with autologous tumour-infiltrating lymphocytes and subcutaneous interleukin-2 in metastatic melanoma <i>M.-H. Tessier, M.-C. Pandolfino, F. Jotereau, D. Boudart, P. Litoux and B. Dréno</i>	735
Beneficial effects of octreotide in a patient with a metastatic paraganglioma <i>F. Tenenbaum, M. Schlumberger, J. Lumbroso and C. Parmentier</i>	737
Rapid tumour lysis syndrome in a metastatic colorectal cancer increased by treatment with irinotecan (CPT-11) <i>M. Boisseau, R. Bugat and M. Mahjoubi</i>	737
Major interactions between radiation therapy and systemic sclerosis: is there an optimal treatment? <i>S. Delanian, C. Maulard-Durdux, J.-L. Lefaix and M. Housset</i>	738

<i>Calendar of Forthcoming Meetings</i>	741
---	-----

Information for Authors	I
-------------------------	---

NUMBER 5

<i>International Cancer News</i>	749
--------------------------------------	-----

Editorial

Defining quality of life <i>S.R. Cohen, B.M. Mount and N. MacDonald</i>	753
--	-----

Special Paper

- Measuring the meaning of life for patients with incurable cancer: the Life Evaluation Questionnaire (LEQ) 755
P. Salmon, F. Manzi and R.M. Valori

Review

- Studies of cancer in migrants: rationale and methodology 761
D.M. Parkin and M. Khat

Clinical Oncology

- Prophylactic cranial irradiation in limited stage small cell lung cancer: survival benefit in patients with favourable characteristics 772
E. Work, S.M. Bentzen, O.S. Nielsen, K. Fode, W. Michalski, T. Palshof and The Aarhus Lung Cancer Group
- Detection of bone marrow metastases in small cell lung cancer. Comparison of magnetic resonance imaging with standard methods 779
M.M.H. Hochstenbag, G. Snoep, N.A.M. Cobben, A.M.W.J. Schols, F.B.J.M. Thunissen, E.F.M. Wouters and G.P.M. ten Velde
- Detection of human papillomavirus DNA in laryngeal squamous cell carcinoma by polymerase chain reaction 783
G. Almadori, G. Cadoni, P. Cattani, P. Posteraro, E. Scarano, F. Ottaviani, G. Paludetti and M. Maurizi
- Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects 789
J. Geisler, D.C. Johannessen, G. Anker and P.E. Lønning
- Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay 793
M. Fernö, P.-O. Bendahl, Å. Borg, J. Brundell, L. Hirschberg, H. Olsson and D. Killander
- Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis 802
G. Flamini, G. Curigliano, C. Ratto, A. Astone, G. Ferretti, P. Nucera, L. Sofo, A. Sgambato, A. Boninsegna, F. Crucitti and A. Cittadini
- A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy 807
B. Audhuy, P. Cappelaere, M. Martin, A. Cervantes, M. Fabbro, A. Rivière, D. Khayat, H. Bleiberg, M. Faraldi and N. Clavierie on behalf of the European Dolasetron Comparative Study Group
- Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial 814
C. Viscoli, E. Castagnola, M.T. Van Lint, C. Moroni, A. Garaventa, M.R. Rossi, R. Fanci, F. Menichetti, D. Caselli, M. Giacchino and M. Congiu

Paediatric Oncology

- Response of previously untreated metastatic rhabdomyosarcoma to combination chemotherapy with carboplatin, epirubicin and vincristine 821
E. Frascella, K. Prichard-Jones, S. Modak, A.F. Mancini, M. Carli and C.R. Pinkerton on behalf of the MMT Working Party of the International Society of Paediatric Oncologists
- Cardiac transplantation in childhood cancer survivors in Great Britain 826
G. Levitt, K. Bunch, C.A. Rogers and B. Whitehead

*Cancer Epidemiology
 and Prevention*

- Substantial variation in therapy for colorectal cancer across Europe: EURO CARE analysis of cancer registry data for 1987 831
G. Gatta, M. Sant, J.W. Coebergh, T. Hakulinen and the EURO CARE Working Group
- Risk factors for invasive cervix cancer in young women 836
J. Cuzick, P. Sasieni and A. Singer

Experimental Oncology

- Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D₃ and the vitamin D₃ analogue EB1089 842
T. Vink-van Wijngaarden, H.A.P. Pols, C.J. Buurman, J.C. Birkenhäger and J.P.T.M. van Leeuwen
- Differential responsiveness of proliferation and cytokeratin release to stripped serum and oestrogen in the human breast cancer cell line, MCF-7 849
T. Tedone, M. Correale, A. Paradiso and S.J. Reshkin
- Modulation of P-glycoprotein mediated drug accumulation in multidrug resistant CCRF VCR-1000 cells by chemosensitisers 857
R. Boer, V. Gekeler, W.-R. Ulrich, P. Zimmermann, W. Ise, A. Schödl and S. Haas
- Serum can inhibit reversal of multidrug resistance by chemosensitisers 862
M. Lehnert, R. de Giuli, K. Kunke, S. Emerson, W.S. Dalton and S.E. Salmon
- The effect of exogenous gangliosides on matrix metalloproteinase secretion by human glioma cells *in vitro* 868
S.L. Maidment, A. Merzak, S. Koochekpour, H.K. Rooprai, G.J. Rucklidge and G.J. Pilkington
- Prevalence of serum antibodies to synthetic peptides to HPV16 epitopes among Indian women with cervical neoplasia 872
B.K. Sharma, A. Ray and N.S. Murthy
- Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin 877
G. Scambia, R. De Vincenzo, F.O. Ranelletti, P. Benedetti Panici, G. Ferrandina, G. D'Agostino, A. Fattorossi, E. Bombardelli and S. Mancuso

Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours	883
<i>B. Jonsson, G. Liming, K. Csoka, H. Fridborg, S. Dhar, P. Nygren and R. Larsson</i>	

Short Communications

Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8°C whole body hyperthermia in patients with refractory sarcoma	888
<i>G. J. Wiedemann, H. I. Robins, S. Gutsche, M. Mentzel, M. Deeken, D. M. Katschinski, S. Eleftheriadis, R. Crahe, C. Weiss, B. Storer and T. Wagner</i>	
Contribution of cervical ultrasound and ultrasound fine-needle aspiration biopsy to the staging of thoracic oesophageal carcinoma	893
<i>S. Bonvalot, N. Bouvard, P. Lothaire, J. Maurel, F. Galateau, P. Ségol and M. Gignoux</i>	
Loss of heterozygosity at the <i>DCC</i> gene locus is not crucial for the acquisition of metastatic potential in oesophageal squamous cell carcinoma	896
<i>C. Maesawa, G. Tamura, S. Ogasawara, Y. Suzuki, K. Sakata, J. Sugimura, S. Nishizuka, N. Sato, K. Ishida, K. Saito and R. Satodate</i>	

Letters

Phase II trial of epirubicin at standard dose in relapsed ovarian cancer	899
<i>I. Peláez, A. J. Lacave, I. Palacio, E. Alvarez, J. F. Cueva, I. Muñiz, F. Arranz and J. Fra</i>	
Follow-up for stage 1 teratoma surveillance patients	900
<i>F. Lander, S. MacBride, L. Samuel, G. Howard and M. Cornbleet</i>	
Single agent paclitaxel in advanced squamous cell head and neck carcinoma	901
<i>V. Gebbia, A. Testa, G. Cannata and N. Gebbia</i>	
Primary Ki-1 lymphoma and the aetiology of B symptoms	902
<i>N. O'Rourke, S. Kelly, T. Vulliamy and P. Price</i>	

Correction	904
------------	-----

Calendar of Forthcoming Meetings	905
----------------------------------	-----

Information for Authors	I
-------------------------	---

NUMBER 6

Special Issue: Multidrug Resistance in Cancer

Foreword	911
Clinical multidrug resistance in cancer: a multifactorial problem	912
<i>M. Lehnert</i>	

Apoptosis and chemotherapy resistance <i>J.A. Hickman</i>	921
P-glycoprotein—a mediator of multidrug resistance in tumour cells <i>U.A. Germann</i>	927
Biology of the multidrug resistance-associated protein, MRP <i>D.W. Loe, R.G. Deeley and S.P.C. Cole</i>	945
Antitopoisomerase drug action and resistance <i>J.L. Nitiss and W.T. Beck</i>	958
Glutathione and related enzymes in multidrug resistance <i>M.L. O'Brien and K.D. Tew</i>	967
Major vault protein LRP-related multidrug resistance <i>M.A. Izquierdo, G.L. Scheffer, M.J. Flens, A.B. Schroeijers, P. van der Valk and R. J. Scheper</i>	979
What have we learnt thus far from mice with disrupted P-glycoprotein genes? <i>P. Borst and A.H. Schinkel</i>	985
Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers <i>J.M. Ford</i>	991
Experimental modulation of MRP (multidrug resistance-associated protein)-mediated resistance <i>P.R. Twentyman and C.H.M. Versantvoort</i>	1002
Oligonucleotide modulation of multidrug resistance <i>D.Y. Bouffard, T. Ohkawa, H. Kijima, A. Irie, T. Suzuki, L.D. Curcio, P. S. Holm, A. Sassani and K.J. Scanlon</i>	1010
Transfer of the <i>MDR1</i> gene into haematopoietic cells <i>M. Baudard, I. Pastan and M.M. Gottesman</i>	1019
How to probe clinical tumour samples for P-glycoprotein and multidrug resistance-associated protein <i>H.J. Broxterman, J. Lankelma and H.M. Pinedo</i>	1024
<i>MDR1</i> /P-glycoprotein in haematological neoplasms <i>J.-P. Marie, D.-C. Zhou, S. Gurbuxani, O. Legrand and R. Zittoun</i>	1034
<i>MDR1</i> gene expression in solid tumours <i>L.J. Goldstein</i>	1039
Diagnosis and reversal of multidrug resistance in paediatric cancers <i>H.S.L. Chan, T.M. Grogan, G. DeBoer, G. Haddad, B.L. Gallie and V. Ling</i>	1051
Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies <i>P. Sonneveld</i>	1062

Clinical trials of P-glycoprotein reversal in solid tumours <i>D.R. Ferry, H. Traunecker and D.J. Kerr</i>	1070
Pharmacological considerations in the modulation of multidrug resistance <i>G.A. Fisher, B.L. Lum, J. Hausdorff and B.I. Sikic</i>	1082
Information for Authors	I

NUMBER 7

<i>International Cancer News</i>	1089
--------------------------------------	------

Editorials

PSA and prostate cancer diagnosis <i>P. Savage and J. Waxman</i>	1097
Ifosfamide and paediatrics: should this marriage be saved? <i>R.B. Womer</i>	1100

Special Paper

Accuracy of admission and clinical diagnosis of tumours as revealed by 2000 autopsies <i>B. Szende, G. Kendrey, K. Lapis, F.J.C. Roe and P.N. Lee</i>	1102
--	------

Reviews

Carcinoid of the pancreas: clinical characteristics and morphological features <i>C.A. Maurer, H.-U. Baer, T.H. Dyong, E. Mueller-Garamvoelgyi, H. Friess, C. Ruchti, J.-C. Reubi and M.W. Büchler</i>	1109
Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma <i>C. Penna and B. Nordlinger</i>	1117

Meeting Highlight

Second International Symposium on Febrile Neutropenia, Brussels, 14–16 December 1995 <i>U. Hess</i>	1123
--	------

Clinical Oncology

Value of PSA (prostate-specific antigen) in the detection of prostate cancer in patients with urological symptoms. Results of a multicentre study <i>X. Filella, R. Molina, A.M. Ballesta, M.J. Gil, C. Allepuz, L.A. Rioja and the Cooperative Group for the Diagnosis of Prostate Cancer</i>	1125
---	------

Genitourinary group phase II study of chemotherapy in stage T3–4 N0–X M0 transitional cell cancer of the bladder: prognostic factor analysis <i>T.A.W. Splinter, M. Pavone-Macaluso, D. Jacqmin, J.T. Roberts, P. Carpentier, M. de Pauw and T. Sahmoud</i>	1129
Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution <i>G. Buccheri, D. Ferrigno and M. Tamburini</i>	1135
Effect of home care on the place of death of advanced cancer patients <i>F. De Conno, A. Caraceni, L. Groff, C. Brunelli, I. Donati, M. Tamburini and V. Ventafridda</i>	1142
Immunohistochemical evaluation of multiple biological markers in ductal carcinoma <i>in situ</i> of the breast <i>T. Perin, V. Canzonieri, S. Massarut, E. Bidoli, C. Rossi, M. Roncadin and A. Carbone</i>	1148
Pre-operative serum levels of CA 242 and CEA predict outcome in colorectal cancer <i>M. Carpelan-Holmström, C. Haglund, J. Lundin, H. Järvinen and P. Roberts</i>	1156
Economic analysis of the use of recombinant human granulocyte colony stimulating factor in autologous bone marrow transplantation <i>E. Souëtre, W. Qing and P.F. Pénelaud</i>	1162
Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma <i>I. Elomaa, L. Risteli, M. Laakso, R. Lahtinen, P. Virkkunen and J. Risteli for the Finnish Leukaemia Group</i>	1166
An open phase I study to assess the biological effects of a continuous intravenous infusion of interleukin-3 followed by granulocyte macrophage-colony stimulating factor <i>S. Bretti, M.H. Gilleece, A. Kamthan, L. Fitzsimmons, F. Hicks, M. Rowlands, P. Bishop, A.-M. Picardo, T.M. Dexter and J.H. Scarffe</i>	1171

Paediatric Oncology

Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics <i>A.V. Boddy, M. English, A.D.J. Pearson, J.R. Idle and R. Skinner</i>	1179
<i>Review</i>	
Monitoring chemotherapy-induced hearing loss in children <i>S.C. Bellman</i>	1185

Cancer Epidemiology and Prevention

An ecological study of cancer incidence and radon levels in South West England <i>D.J. Etherington, D.F.H. Pheby and F.I. Bray</i>	1189
Variations in the screening history and appropriateness of management of cervical cancer in South East England <i>C.D.A. Wolfe, K. Tilling, H.M. Bourne and K.S. Raju</i>	1198

Experimental Oncology

DNA amplification on chromosome 3q26.1–q26.3 in squamous cell carcinoma of the lung detected by reverse chromosome painting <i>N. Brass, I. Ukena, K. Remberger, U. Mack, G.W. Sybrecht and E.U. Meese</i>	1205
Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis <i>J. Musarrat, J. Arezina-Wilson and A.A. Wani</i>	1209
Elevated serum E-selectin in patients with liver metastases of colorectal cancer <i>B.M. Wittig, H. Kaulen, R. Thees, C. Schmitt, P. Knolle, J. Stock, K.H. Meyer zum Büschenfelde and W. Dippold</i>	1215
Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: <i>in vitro</i> synergistic cytotoxicity and DNA-induced strand-breaks <i>M. Andreuccetti, G. Allegrini, A. Antonuzzo, G. Malvaldi, P.F. Conte, R. Danesi, M. Del Tacca and A. Falcone</i>	1219
The activity and expression of thymidine phosphorylase in human solid tumours <i>Y. Takebayashi, K. Yamada, K. Miyadera, T. Sumizawa, T. Furukawa, F. Kinoshita, D. Aoki, H. Okumura, Y. Yamada, S.-i. Akiyama and T. Aikou</i>	1227
Phenotypic and functional characterisation of tumour-infiltrating lymphocytes derived from thyroid tumours <i>R.S. Lee, M. Schlumberger, B. Caillou, F. Pages, W.H. Fridman and E. Tartour</i>	1233
[²¹¹ At]Methylene blue for targeted radiotherapy of human melanoma xenografts: dose fractionation in the treatment of cutaneous tumours <i>E.M. Link, R.N. Carpenter and G. Hansen</i>	1240
Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways <i>J.R.W. Masters, R. Thomas, A.G. Hall, L. Hogarth, E.C. Matheson, A.R. Cattam and H. Lohrer</i>	1248

Short Communications

Phase II trial of <i>N</i> -(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon- α -2b in patients with advanced gastric carcinoma <i>S. Wadler, B. Gleissner, R.U. Hilgenfeld, E. Thiel, H. Haynes, R. Kaleya, A. Rozenblit and E.-D. Kreuser</i>	1254
Long-term positron emission tomography evaluation of slowly progressive gliomas <i>K. Mineura, T. Sasajima, M. Kowada, T. Ogawa, J. Hatazawa and K. Uemura</i>	1257

Letters

Bronchioloalveolar carcinoma presenting aerogenous metastasis to the upper airway <i>N. Hidaka, Y. Hidaka, Y. Tajima, I. Sugano and K. Nagao</i>	1261
---	------

Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease <i>F. Tenenbaum, C. Corone, M. Schlumberger and C. Parmentier</i>	1262
Increasing the dose intensity of chemotherapy by means of granulocyte-colony stimulating factor (G-CSF) support in the treatment of small cell lung cancer (SCLC) <i>D.J. Girling, N. Thatcher, P.I. Clark and R.J. Stephens</i>	1263
<i>Correction</i>	1264
<i>Calendar of Forthcoming Meetings</i>	1265
Information for Authors	I
NUMBER 8	
Message from the Editor-in-Chief	1271
<i>International Cancer News</i>	1273
<i>Editorials</i>	
Multiple primary cancers in population-based cancer registries <i>M.M. Hawkins</i>	1279
Health-related quality of life, cancer and health care <i>M.E.M. Jenney</i>	1281
<i>Review</i>	
Cancer: a challenge for control theory and computer modelling <i>W. Dürching, W. Ulmer and T. Ginsberg</i>	1283
<i>Point of View</i>	
Obesity, social class and Western diet: a link to breast cancer prognosis <i>B.A. Stoll</i>	1293

Special Paper

- Continuing Medical Education in Oncology in Europe 1296
J.P. Armand, A. Costa, J. Geraghty, N. O'Higgins, P.J. Broe, L. Holmberg, D.Th. Sleijfer and J. de Toeu

Meeting Highlight

- Cancer research in the European Community—report from a meeting in Stockholm in 1995 1300
G. Gahrton, A. Graessmann, F. Meunier, M. Schmitt, J.J.M. Van Dongen and S.S. Baig

Clinical Oncology

- Sex as a prognostic factor in gastric cancer 1303
A. Maguire, M. Porta, J.M. Sanz-Anquela, I. Ruano, N. Malats and J.L. Piñol
- Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study 1310
D.J.Th. Wagener, W.J. Hoogenraad, Ph. Rougier, A. Lusinchi, B.G. Taal, C.H.N. Veenhof, A. de Graeff, T. Conroy, D. Curran, T. Sahmoud and J. Wils
- Feasibility of escalating daily doses of cisplatin in combination with accelerated radiotherapy in non-small cell lung cancer 1314
A.L.J. Schuster-Uiterhoeve, P.J.M. van de Vaart, C.C.E. Schaake-Koning, J. Benraadt, M.G.J. Koolen, D. González González and H. Bartelink
- Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer 1320
P. Sagaster, J. Flamm, M. Flamm, A. Mayer, G. Donner, S. Oberleitner, L. Havelec, L. Lepsinger and H. Ludwig
- Humoral immune response to polymorphic epithelial mucin (*MUC-1*) in patients with benign and malignant breast tumours 1325
S. von Mensdorff-Pouilly, M.M. Gourevitch, P. Kenemans, A.A. Verstraeten, S.V. Litvinov, G.J. van Kamp, S. Meijer, J. Vermorken and J. Hilgers
- Early identification of neutropenic patients at risk of gram-positive bacteraemia and the impact of empirical administration of vancomycin 1332
E.C. Dompeling, J.P. Donnelly, S.C. Deresinski, R. Feld, E.F. Lane-Allman and B.E. De Pauw for The Intercontinental Antimicrobial Study Group
- Is there a role for melatonin in the treatment of neoplastic cachexia? 1340
P. Lissoni, F. Paolorossi, G. Tancini, S. Barni, A. Ardizzoia, F. Brivio, B. Zubelewicz and V. Chatikhine
- Attitudes toward informing the cancer patient—a survey of Norwegian physicians 1344
J.H. Loge, S. Kaasa, Ø. Ekeberg, E. Falkum and K. Hytten
- Human papilloma virus has no prognostic significance in cervical carcinoma 1349
G.B. Kristensen, F. Karlsen, A. Jenkins, J. Kærn, V.M. Abeler and C.G. Tropé

Paediatric Oncology

- Health-related quality of life of adults surviving malignancies in childhood 1354
M. Apajasalo, H. Sintonen, M.A. Siimes, L. Hovi, C. Holmberg, H. Boyd, A. Mäkelä and J. Rautonen
- A new germline *TP53* gene mutation in a family with Li-Fraumeni syndrome 1359
B. Dockhorn-Dworniczak, J. Wolff, C. Poremba, K.-L. Schäfer, J. Ritter, F. Gullotta, H. Jürgens and W. Böcker

*Cancer Epidemiology
and Prevention*

- Problems related to the coding of multiple primary cancers 1366
E. Crocetti, S. Lecker, E. Buiatti and H.H. Storm

Experimental Oncology

- Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 Workshop 1371
Th.J. Benraad, J. Geurts-Moespot, J. Grøndahl-Hansen, M. Schmitt, J.J.T.M. Heuvel, J.H. de Witte, J.A. Foekens, R.E. Leake, N. Brünner and C.G.J. Sweep
- Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites 1382
E. Boven, J. de Jong, C.M. Kuiper, A. Bast and W.J.F. van der Vijgh
- p53 expression, DNA content and cell proliferation in primary and synchronous metastatic lesions from ovarian surface epithelial-stromal tumours 1388
M.G. Daidone, E. Benini, B. Valentini, G. Tomasic, G. Bolis, A. Villa and R. Silvestrini
- Expression of CD44 isoforms in human skin cancer 1394
J.C. Simon, K.-H. Heider, A. Dietrich, C. Wuttig, E. Schöpf, G.R. Adolf, H. Ponta and P. Herrlich
- Augmented expression of *LCK* message directed from the downstream promoter in human colorectal cancer specimens 1401
K. Nakamura, Y. Chijiwa and H. Nawata
- Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferon γ (IFN γ) are recognised by T cells while resisting destruction by natural killer (NK) cells 1408
K.S. Zier and B. Gansbacher
- Tumour growth and fetal uptake of amino acids in the pregnant rat 1413
N. Carbó, F.J. López-Soriano and J.M. Argilés
- In vitro* induction of differentiation by ginsenosides in F9 teratocarcinoma cells 1420
Y.-N. Lee, H.-Y. Lee, H.-Y. Chung, S.-I. Kim, S.-K. Lee, B.-C. Park and K.-W. Kim

Short Communications

- Somatostatin receptor imaging in small cell lung cancer 1429
N. Berenger, J.L. Moretti, C. Boaziz, N. Vigneron, J.F. Morere and J.L. Breaux

Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group) <i>Ph. Rougier, C. Van Pottelsberghe, T. Kok, B. Paillot, T. Wagener, J. De Greve, M.C. Fabri, B. Gerard, M. Van Glabbeke, H. Bleiberg and the EORTC-GITCCG</i>	1432
---	------

Letters

Letter to the Editor: Prostate cancer. An insight into screening and local treatment <i>M. Bolla and H. Van Poppel</i>	1434
Male breast cancer: statistical and clinical data for the Maltese population <i>M. Gixti, M. Dalmás and V. Muscat</i>	1435
High-dose recombinant interleukin-2/verapamil combination in advanced cancer <i>P. Tagliaferri, P. Correale, M. Mottola, G. de Simone, V. Montesarchio, E. Matano, A. Rea, A. Morabito, M. Famiani, F. Ciardiello, G. Tortora, M. Garaglia, C. Barile, G. Palmieri and A.R. Bianco</i>	1436
Activity of gemcitabine in platinum-resistant ovarian germ cell cancer <i>K. Maas, T. Daikeler, L. Kanz and C. Bokemeyer</i>	1437

*Calendar of
Forthcoming
Meetings*

1439

Information for Authors

I

NUMBER 9

Announcement

Editorial Office Relocation	1445
-----------------------------	------

*International
Cancer News*

1447

Editor's Page Announcing "Current Controversies in Cancer"	1453
--	------

Editorials

Do we know what's best for prostate cancer? <i>J. Waxman and H. Pandha</i>	1455
Communication skills: when, not if, to teach <i>L.G. Walker</i>	1457

Current
Controversies in
Cancer

- Is routine axillary nodal dissection necessary in the treatment of breast cancer? 1460
PRO: I.S. Fentiman
CONTRA: R. Epstein
ARBITER: L. Barr

Special Paper

- A realistic clinical perspective of tamoxifen and endometrial carcinogenesis 1464
V.Ĵ. Assikis, P. Neven, V.C. Jordan and I. Vergote

Review

- Diagnostic and prognostic implications of genetic lesions in non-Hodgkin's lymphoma 1477
G. Gaidano and A. Carbone

Meeting Highlight

- Third International Symposium on Hodgkin's Lymphoma in Köln, Germany 1483
A. Engert, K. Reuß, H. Tesch and V. Diehl

Clinical Oncology

- Helping health professionals involved in cancer care acquire key interviewing skills—the impact of workshops 1486
P. Maguire, K. Booth, C. Elliott and B. Jones
- The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis 1490
E. van der Wall, C.C.E. Schaake-Koning, N. van Zandwijk, Ĵ.W. Baars, Ĵ.H. Schornagel, D.Ĵ. Richel, E.Ĵ.T. Rutgers, Ĵ.H. Borger, Ĵ.H. Beijnen and S. Rodenhuis
- Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC phase III trial 1498
P.E. Postmus, G. Scagliotti, H.Ĵ.M. Groen, F. Gozzelino, Ĵ.Th.W. Burghouts, D. Curran, T. Sahmoud, A. Kirkpatrick, G. Giaccone and T.A.W. Splinter
- The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: an investigation of their expression as prognostic markers 1504
I. Takanami, F. Tanaka, T. Hashizume, K. Kikuchi, Y. Yamamoto, T. Yamamoto and S. Kodaira
- Treatment costs in Hodgkin's disease: a cost-utility analysis 1510
Ĵ. Norum, V. Angelsen, E. Wist and Ĵ.A. Olsen

Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9 <i>H.L. McLeod, M.A. Graham, S. Aamdal, A. Setanoians, Y. Groot, B. Lund on behalf of the EORTC Early Clinical Trials Group</i>	1518
Therapeutic equivalence of single oral doses of dolasetron mesilate and multiple doses of ondansetron for the prevention of emesis after moderately emetogenic chemotherapy <i>A.A. Fauser, B. Duclos, A. Chemaissani, A. Del Favero, F. Cognetti, E. Diaz-Rubio, H. Cortes-Funes, P.F. Conte, H. Dressler on behalf of the European Dolasetron Comparative Study Group</i>	1523
A phase II study of dacarbazine, cisplatin, interferon- α and high-dose interleukin-2 in 'poor-risk' metastatic melanoma <i>T.M. Proebstle, C. Scheibenbogen, W. Sterry and U. Keilholz</i>	1530
Suramin-induced neutropenia <i>N.A. Dawson, R.M. Lush, S.M. Steinberg, A.C. Tompkins, D.J. Headlee and W.D. Figg</i>	1534

Paediatric Oncology

<i>Review</i>	
Screening for neuroblastoma: 20 years and still no answer <i>A.W. Craft and L. Parker</i>	1540
Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations <i>J. Boos, G. Werber, E. Ahlke, P. Schulze-Westhoff, U. Nowak-Göttl, G. Würthwein, E.J. Verspohl, J. Ritter and H. Jürgens</i>	1544

Cancer Epidemiology and Prevention

An analysis of alternative classification schemes for medical atlas mapping <i>E.K. Cromley and R.G. Cromley</i>	1551
---	------

Experimental Oncology

The clinical significance of androgen receptors in breast cancer and their relation to histological and cell biological parameters <i>V. Kuenen-Boumeester, T.H. Van der Kwast, C.C. Claassen, M.P. Look, G.S. Liem, J.G.M. Klijn and S.C. Henzen-Logmans</i>	1560
Multiple forms of TGF- β_1 in breast tissues: a biologically active form of the small latent complex of TGF- β_1 <i>R. Baillie, R.C. Coombes and J. Smith</i>	1566
Pharmacological studies with Cetrorelix (SB-75), a potent antagonist of luteinising hormone-releasing hormone <i>Th. Reissmann, Th. Klenner, W. Deger, P. Hilgard, G.P. McGregor, K. Voigt and J. Engel</i>	1574

Effect of regional angiotensin II infusion on the relationship between tumour blood flow and fluorouracil uptake in a liver metastasis animal model <i>M.J. Dworkin, J. Zweit, P. Carmochan, B. Deehan and T.G. Allen-Mersh</i>	1580
pS2 protein expression in gastric carcinoma. An immunohistochemical and immunoradiometric study <i>J.-C. Machado, F. Carneiro, P. Ribeiro, N. Blin and M. Sobrinho-Simões</i>	1585
Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line <i>G. Toffoli, G. Corona, M. Gigante and M. Boiocchi</i>	1591
Expression of the 67 kD laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLC5 <i>F.A. van den Brûle, V. Castronovo, S. Ménard, R. Giavazzi, M. Marzola, D. Belotti and G. Taraboletti</i>	1598
Modulation of [5- ¹²⁵ I]iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors <i>J. Mester, K. DeGoeij and M. Sluyser</i>	1603

Short Communications

Effects of interleukin-1 α on ovarian carcinoma in patients with recurrent disease <i>C.F. Verschraegen, A.P. Kudelka, W. Termrungruanglert, C.G. de Leon, C.L. Edwards, R.S. Freedman, J.J. Kavanagh and S. Vadhan-Raj</i>	1609
The impact of a psychological intervention on quality of life in non-metastatic breast cancer <i>G. Marchioro, G. Azzarello, F. Checchin, M. Perale, R. Segati, E. Sampognaro, F. Rosetti, A. Franchin, G.L. Pappagallo and O. Vinante</i>	1612

Letters

Letters to the Editor: Comments on <i>A Case of Radiation Myelopathy After 2 $\times$ 8.5 Gy for Inoperable Non-small Cell Lung Cancer</i> , Dardoufas <i>et al.</i> , <i>European Journal of Cancer</i> , 31A, Nos 13/14, pp. 2418–2419, 1995 (i) <i>M. Hocking</i> (ii) <i>F. Macbeth</i>	1616
Breast metastases of Merkel cell carcinoma <i>T. Schnabel and M. Glag</i>	1617
Myocardial infarction associated with vinorelbine (Navelbine ^R) <i>A. Zabernigg and C. Gattlinger</i>	1618

Calendar of Forthcoming Meetings

I

Information for Authors

VII

NUMBER 10

<i>International Cancer News</i>	1621
<i>Editorials</i>	
Detection of early micrometastases in malignant melanoma <i>E.M. Rankin</i>	1627
Rheumatoid arthritis and lymphatic cancer <i>G.J. Macfarlane and R.J. Black</i>	1630
<i>Current Controversies in Cancer</i>	
Is isolated limb perfusion of metastatic malignant melanoma of the extremity worthwhile? <i>Pro: H. Schraffordt Koops</i> <i>Contra: C. Garbe</i> <i>Arbiter: P. Hohenberger</i>	1633
<i>Point of View</i>	
Primary treatment in stage II non-seminomatous germ cell tumours of the testis: a matter of scalpel or drug infusion? <i>S. Culine and J.-P. Droz</i>	1641
<i>Special Paper</i>	
Early detection of familial ovarian cancer <i>A. Dørum, G.B. Kristensen, V.M. Abeler, C.G. Tropé and P. Møller</i>	1645
<i>Review</i>	
Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? <i>S.S. Bielack, R. Erttmann, B. Kempf-Bielack and K. Winkler</i>	1652
<i>Meeting Highlight</i>	
Diagnostic PCR in melanoma, methods and quality assurance, Epalinges, Switzerland, 26/27 January 1996 <i>U. Keilholz for the EORTC Melanoma Cooperative Group (Immunotherapy Subgroup)</i>	1661
<i>Clinical Oncology</i>	
Detection of early micrometastases in subcutaneous fat of primary malignant melanoma patients by identification of tyrosinase-mRNA <i>T.M. Proebstle, R. Huber and W. Sterry</i>	1664

A single centre's 10 year experience with isolated limb perfusion in the treatment of recurrent malignant melanoma of the limb <i>M.K. Lingam, D.S. Byrne, T. Aitchison, R.M. MacKie and A.J. McKay</i>	1668
Pain and discomfort during mammography <i>A.R. Aro, P. Absetz-Ylöstalo, T. Eerola, M. Pamilo and J. Lönnquist</i>	1674
Prognostic value of quantitative cytometry in a series of 415 T1T2/N0N1/M0 breast cancer patients—preliminary results <i>M. Bolla, D. Seigneurin, P. Winckel, J. Marron-Charrière, M.H. Panh, D. Pasquier, M. Chédin, R. Payan, F. Merlin and M. Colonna</i>	1680
Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas <i>K. Weber-Chappuis, S. Bieri-Burger and J. Hurlimann</i>	1686
Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas <i>C. Di Loreto, F. Puglisi, G. Rimondi, C. Zuiani, G. Anania, V. Della Mea, and C.A. Beltrami</i>	1693
Correlation between P450 CYP1A1 inducibility, MspI genotype and lung cancer incidence <i>M. Jacquet, V. Lambert, E. Baudoux, M. Muller, P. Kremers and J. Gielen</i>	1701
Enhanced acute toxicity in oropharynx carcinoma treated with radiotherapy and concomitant cisplatin, 5-fluorouracil and mitomycin C <i>C. Berger, S. Chapet, A. Reynaud-Bugnoux, G. Garand, O. Le Floch and G. Calais</i>	1707
Phase II trial of intravenous endotoxin in patients with colorectal and non-small cell lung cancer <i>F. Otto, P. Schmid, A. Mackensen, U. Wehr, A. Seiz, M. Braun, C. Galanos, R. Mertelsmann and R. Engelhardt</i>	1712
Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies <i>P. Comella, G. Palmieri, V. Lorusso, G. Catalano, D. Nicollela, G.P. Ianniello, R. Casaretti, M. Montella, G. Frasci, M. Perna and G. Comella</i>	1719
Patterns of failure following treatment of pseudomyxoma peritonei of appendiceal origin <i>F.A.N. Zoetmulder and P.H. Sugarbaker</i>	1727
Evaluation of a prediction model of cisplatin dose based on total platinum plasma concentration <i>B. Desoize, G. Berthiot, L. Manot, P. Coninx and P. Dumont</i>	1734
Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients <i>J. Aparicio, A. Oltra, C. Llorca, J. Montalar, C. Herranz, J. Gómez-Codina, M. Pastor and B. Munárriz</i>	1739

Paediatric Oncology

An increased loading dose of ondansetron: a North European, double-blind randomised study in children, comparing 5 mg/m ² with 10 mg/m ² <i>P. Brock, B. Brichard, C. Rechnitzer, N.E. Langeveld, M. Lanming, S. Söderhäll and C. Laurent</i>	1744
--	------

Constitutional nonsense germline mutations in the <i>RB1</i> gene detected in patients with early onset unilateral retinoblastoma <i>J.K. Cowell and H. Cragg</i>	1749
--	------

Cancer Epidemiology and Prevention

Rheumatoid arthritis and cancer risk <i>L. Mellemkjær, M.S. Linet, G. Gridley, M. Frisch, H. Møller and J.H. Olsen</i>	1753
---	------

Experimental Oncology

Adaptation of the Cellscan technique for the SCM test in breast cancer <i>H. Rahmani, M. Deutsch, I. Ron, S. Gerbat, R. Tirosh, A. Weinreb, S. Chaichik and S. Lalchuk</i>	1758
Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines <i>N. Zaffaroni, L. Orlandi, D. Gornati, C. De Marco, M. Vaglini and R. Silvestrini</i>	1766
Improved efficacy of chemotherapy by parvovirus-mediated sensitisation of human tumour cells <i>P. Klein-Bauernschmitt, M. von Knebel Doeberitz, M. Ehrbar, K. Geletneky, J. Kleinschmidt and J.R. Schlehofer</i>	1774
High molecular weight phospholipase A ₂ and fatty acids in human colon tumours and associated normal tissue <i>A.S. Soydan, I.A. Tavares, P.K. Weech, N.M. Tremblay and A. Bennett</i>	1781
Alteration in mucin gene expression and biological properties of HT29 colon cancer cell subpopulations <i>H. Kitamura, M. Cho, B.H. Lee, J.R. Gum, B.B. Siddiki, S.B. Ho, N.W. Toribara, T. Lesuffleur, A. Zweibaum, Y. Kitamura, S. Yonezawa and Y.S. Kim</i>	1788
Allele loss on chromosome 11q and microsatellite instability in malignant melanoma <i>I.P.M. Tomlinson, N.E. Beck and W.F. Bodmer</i>	1797
Effects of chronic administration of <i>N</i> -(4-hydroxyphenyl)retinamide (4-HPR) in rats on vitamin A metabolism in the eye <i>K.C. Lewis, L.A. Zech and J.M. Phang</i>	1803

Short Communications

Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients <i>A. Veronesi, D. Crivellari, M.D. Magri, G. Cartei, M. Mansutti, S. Foladore and S. Monfardini</i>	1809
Soft tissue sarcomas in HIV-infected adult patients <i>K. Fizazi, J. Feuillard, A. Le Cesne, P. Terrier, M. Raphael, P. Pouillart and T. Tursz</i>	1812
Modulation of toxicity following external beam irradiation preceded by high-dose rate brachytherapy in inoperable oesophageal cancer <i>B.G. Taal, B.M.P. Aleman, C.C.E. Koning and H. Boot</i>	1815

Letters

Type C hepatitis and chronic lymphocytic leukaemia <i>L. La Civita, A.L. Zignego, M. Monti, G. Longombardo, F. Greco, G. Pasero and C. Ferri</i>	1819
Angiosarcoma of the breast after conservative surgery and radiation therapy for breast carcinoma: three new cases <i>J.L. Molitor, M. Spielmann and G. Contesso</i>	1820
Severe cutaneous reactions following interferon injections <i>M. Azagury, C. Pauwels, S. Kornfeld, N. Bataille and G. Perie</i>	1821
Single agent paclitaxel in the treatment of unresectable and/or metastatic pancreatic adenocarcinoma <i>N. Gebbia and V. Gebbia</i>	1822
Serum neuron-specific enolase (NSE) as a tumour marker for the Ewing's sarcoma family of tumours <i>K. Fizazi, A. Le Cesne, N. Dohollou, S. Affaied, M. Spielmann and T. Le Chevalier</i>	1823
Transaxillary access to perform hepatic artery infusion (HAI) for secondary or primitive hepatic tumours <i>C. Zanon and M. Grosso</i>	1824

Calendar of
Forthcoming
Meetings

I

Information for Authors

V

NUMBER 11

International
Cancer News

1827

Editorial

Bioreductive agents, hypoxic cells and therapy <i>T. A. Connors</i>	1833
--	------

Current
Controversies in
Cancer

Is mass screening for breast cancer cost-effective? <i>Pro: H.J. de Koning</i> <i>Contra: J.W.W. Coebergh</i> <i>Arbiter: J.A. van Dongen</i>	1835
--	------

Point of View

- Mixing anthracyclines and radiotherapy in early breast cancer: how safe is it? 1845
P. HjiYiannakis and J.R. Yarnold

Special Paper

- The marriage of pathology and genetics in soft tissue tumours: EACR—Mühlbock Memorial Lecture 1849
H. Van den Berghe

Review

- Transcription factors as drug targets in cancer 1857
H.C. Hurst

Meeting Highlight

- In the shadow of Chernobyl—A report of the First International Conference of the European Commission, Belarus, Russian Federation and Ukraine on the radiological consequences of the Chernobyl accident, 18–22 March 1996, Minsk, Belarus 1864
H.H. Storm

Clinical Oncology

- Comparison of the surgical procedures for breast conserving treatment of early breast cancer in seven EORTC centres 1866
M.R. Christiaens, L. Cataliotti, I. Fentiman, E. Rutgers, M. Blichert-Toft, J.E. DeVries, H.P. Graversen, K. Vantongelen and R. Aerts
- Characterisation of complete responders to combination chemotherapy for advanced breast cancer: a retrospective EORTC breast group study 1876
E. Tomiak, M. Piccart, F. Mignolet, T. Sahmoud, R. Paridaens, M. Nooy, L. Beex, I.S. Fentiman, A. Muller, E. van der Schueren and R.D. Rubens on behalf of the EORTC Breast Cancer Cooperative Group
- A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer 1888
N.S.A. Stuart, J. Warwick, G.R.P. Blackledge, D. Spooner, C. Keen, A.R. Taylor, C. Tyrell, D.J.T. Webster and H. Earl
- Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung 1893
O. Brodin, E. Nou, C. Mercke, C.J. Lindén, R. Lundström, Å. Arwidi, J. Brink and U. Ringborg for the Swedish Lung Cancer Study Group
- Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer 1901
R. V. Iaffaioli, F. Caponigro, A. Tortoriello, G. Facchini, V. Ravo, M. Maccauro, P. Dimitri, F. Crovella and P. Muto

Phase I/II trial of autologous activated macrophages in advanced colorectal cancer <i>J.C. Eymard, M. Lopez, A. Cattani, O. Bouché, J.C. Adjizian and J. Bernard</i>	1905
Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer <i>J.M. Blazeby, D. Alderson, K. Winstone, R. Steyn, E. Hammerlid, J. Arraras and J.R. Farndon on behalf of the EORTC Quality of Life Study Group</i>	1912
Multivariate analysis of prognostic factors in 106 patients with malignant glioma <i>E. Salminen, J.M. Nuutinen and S. Huhtala</i>	1918
Combined diagnostic imaging with ¹³¹ I-metaiodobenzylguanidine and ¹¹¹ In-pentetreotide in carcinoid tumours <i>B.G. Taal, C.A. Hoefnagel, R.A. Valdés Olmos and H. Boot</i>	1924
A phase II study of 5-fluorouracil, leucovorin and cisplatin (FLP) for metastatic gastric cancer <i>M. Ychou, C. Astre, Ph. Rouanet, J.M. Fabre, B. Saint-Aubert, J. Domergue, D. Ribard, A.J. Ciurana, Ch. Janbon and H. Pujol</i>	1933

Paediatric Oncology

High-dose melphalan followed by autograft employing non-cryopreserved peripheral blood progenitor cells in children <i>N. Jones, D. Williams, V. Broadbent, K. Jestic, P. Boraks, M. Scott, S. Ager and R. Marcus</i>	1938
Childhood leukaemia and exposure to pesticides: results of a case-control study in Northern Germany <i>R. Meinert, P. Kaatsch, U. Kaletsch, F. Krummenauer, A. Miesner and J. Michaelis</i>	1943

Epidemiology and Cancer Prevention

<i>Review</i>	
An improved statistical approach: can it clarify the role of new prognostic factors for breast cancer? <i>J.W. Chapman, D. Murray, D.R. McCready, W. Hanna, H.J. Kahn, H.L.A. Lickley, M.E. Trudeau, B.G. Mobbs, C.A. Sawka, E.B. Fish and K.I. Prichard</i>	1949
Clinical features, frequency and prognosis of Dukes' A colorectal carcinoma: a population-based investigation <i>C. Di Gregorio, R. Fante, L. Roncucci, M.G. Tamassia, L. Losi, P. Benatti, M. Pedroni, A. Percesepe, S. De Pietri and M. Ponz de Leon</i>	1957

Experimental Oncology

Prognostic significance of p53 nuclear and cytoplasmic overexpression in right and left colorectal adenocarcinomas <i>X.-F. Sun, J.M. Carstensen, H. Zhang, G. Arbmán and B. Nordenskjöld</i>	1963
--	------

Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer <i>in vivo</i> and <i>in vitro</i> <i>M.H. Seelig and M.R. Berger</i>	1968
Epidermal growth factor (EGF) increases the <i>in vitro</i> invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704 <i>J.T. Price, H.M. Wilson and N.E. Haites</i>	1977
Evidence that cisplatin induces serotonin release from human peripheral blood mononuclear cells and that methylprednisolone inhibits this effect <i>G. Mantovani, A. Macciò, S. Esu and P. Lai</i>	1983
²¹¹ At-methylene blue for targeted radiotherapy of disseminated melanoma: microscopic analysis of tumour versus normal tissue damage <i>E.M. Link, A.S. Michalowski and F. Rösch</i>	1986
Capsaicin inhibits plasma membrane NADH oxidase and growth of human and mouse melanoma lines <i>D.J. Morré, E. Sun, C. Geilen, L.-Y. Wu, R. de Cabo, K. Krasagakis, C.E. Orfanos and D.M. Morré</i>	1995
Amplification of <i>ERBB</i> oncogenes in squamous cell carcinomas of the head and neck <i>J.P. Rodrigo, S. Ramos, P.S. Lazo, I. Alvarez and C. Suárez</i>	2004
<i>In vitro</i> and <i>in vivo</i> characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin <i>G. Belvedere, L. Imperatori, G. Damia, G. Tagliabue, C. Meijer, E.G.E. de Vries and M. D'Incalci</i>	2011

Short Communications

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group <i>L.Y. Dirix, F. Tonnesen, J. Cassidy, R. Epelbaum, W.W. ten Bokkel Huinink, N. Pavlidis, R. Sorio, T. Gamucci, I. Wolff, A. Te Velde, J. Lan and J. Verweij</i>	2019
Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer <i>C. Tempfer, A. Lösch, H. Heinzl, G. Häusler, E. Hanzal, H. Kölbl, G. Breitenecker and Ch. Kainz</i>	2023
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma <i>A.S.T. Planting, M.E.L. van der Burg, S.H. Goey, J.H.M. Schellens, Ch. Vecht, M. de Boer-Dennert, G. Stoter and J. Verweij</i>	2026

Letters

Letters to the Editor: Comments on <i>Does Age at Last Birth Affect Breast Cancer Risk?</i> , Hsieh <i>et al.</i> , <i>European Journal of Cancer</i> , 32A, No. 1, pp. 118–121, 1996 (i) <i>A. Maguire and A. Kalache</i> (ii) <i>Response from C.-C. Hsieh et al.</i>	2029
---	------

Letters to the Editor: Comments on <i>Palliative Endoscopic Therapy of Rectal Carcinoma</i> , Dohmoto <i>et al.</i> , <i>European Journal of Cancer</i> , 32A, No. 1, pp. 25–29, 1996	2031
(i) R. Glynn-Jones and P.J. Hoskin	
(ii) J.-F. Bosset, J.-J. Pavy, V. Magnin, H.P. Hamers and J.-C. Horiot	

Calendar of Forthcoming Meetings	I
--	---

Information for Authors	V
-------------------------	---

NUMBER 12

International Cancer News	2033
------------------------------	------

Editorial

Cancer and the mind—do we still believe Galen? F. Stiefel and P. Guex	2041
--	------

Review

The diagnostic information of tests for the detection of cancer: the usefulness of the likelihood ratio concept R.W.M. Giard and J. Hermans	2042
---	------

Clinical Oncology

Life events and the risk of breast cancer: a case–control study A. Ginsberg, S. Price, D. Ingram and E. Nottage	2049
--	------

Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy—a pilot study of the German Myeloma Treatment Group (GMTG) D. Peest, H. Deicher, W. Fett, P. Harms, H.J. Braun, M. Planker, U. Kindler, C. Klinkenstein, E. Schäfer, K. Schumacher and H. Siecke	2053
--	------

High-dose melphalan with re-infusion of unprocessed, G-CSF-primed whole blood is effective and non-toxic therapy in multiple myeloma G.J. Ossenkoppele, G.J. Schuurhuis, A.R. Jonkhoff, K.G. van der Hem, M.C.J.C. Legdeur, A. Boot-Bakker, A.H. Westra, A.M. Dräger and P.C. Huijgens	2058
---	------

Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study A. Favaretto, A. Paccagnella, L. Tomio, F. Sartori, A. Cipriani, R. Zuin, L. Reffosco, F. Calabro', F. Rea, C. Ghiotto, V. Chiarion-Sileni, F. Oniga, L. Loreggian and M.V. Fiorentino	2064
---	------

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer	2070
<i>S. Fujino, T. Enokibori, N. Tezuka, Y. Asada, S. Inoue, H. Kato and A. Mori</i>	
No age limit for radical radiotherapy in head and neck tumours	2075
<i>T. Pignon, J.-C. Horiot, W. Van den Bogaert, M. Van Glabbeke and P. Scalliet</i>	
A comparison of dosimetric methods in isolated limb perfusion with melphalan for malignant melanoma of the lower extremity	2082
<i>D.S. Byrne, A.J. McKay, R. Blackie and R.M. MacKie</i>	
Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer	2088
<i>M.-E. Toubert, J. Guillet, M. Chiron, P. Meria, C. Role, M.-H. Schlageter, H. Francois, C. Borschneck, F. Nivelon, F. Desgrandchamps, D. Rastel, O. Cussenot, P. Teillac, A. Le Duc and Y. Najean</i>	

Paediatric Oncology

<i>Review</i> Fibromatosis and fibrosarcoma in infancy and childhood	2094
<i>C. Fisher</i>	
Time course of methotrexate polyglutamate formation and degradation in the pre-B-leukaemia cell line Nalm6 and in lymphoblasts from children with leukaemia	2101
<i>B. Buchholz, E. Frei, J. Eisenbarth, M. Weigand and R. Ludwig</i>	

Epidemiology and Cancer Prevention

Alcohol and breast cancer in the Swiss Canton of Vaud	2108
<i>F. Levi, C. Pasche, F. Lucchini and C. La Vecchia</i>	
Survival in small intestinal adenocarcinoma	2114
<i>N. Zar, L. Holmberg, E. Wilander and J. Rastad</i>	

Experimental Oncology

Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue	2120
<i>P.C. Gorge, M.J. Hulme, R.A. Clegg and W.R. Miller</i>	
Induction of metalloproteinase (MMP1) expression by epidermal growth factor (EGF) receptor stimulation and serum deprivation in human breast tumour cells	2127
<i>J.E. Nutt and J. Lunec</i>	
Rapid recovery of a functional MDR phenotype caused by MRP after a transient exposure to MDR drugs in a revertant human lung cancer cell line	2136
<i>R. Gonzalez Manzano, C. Versanvoort, K. Wright and P.R. Twentyman</i>	

Detection of interleukin-8 mRNA and protein in human colorectal carcinoma cells <i>R. Brew, S.A. Southern, B.F. Flanagan, I.W. McDicken and S.E. Christmas</i>	2142
The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line <i>P.G. Johnston, F. Geoffrey, J. Drake, D. Voeller, J.L. Grem and C.J. Allegra</i>	2148
Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat region <i>C. Petrarca, A. Ruggetti, H. Rahimi, F. D'Agostini, V. Turchi, C. Apollonj Ghetti, G. Scambia, L. Frati and M. Nuti</i>	2155
Tunicamycin potentiates drug cytotoxicity and vincristine retention in multidrug resistant cell lines <i>D. Hiss, G. Gabriels, P. Jacobs and P. Folb</i>	2164

Short Communications

Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancer <i>M.M. Borner, M. Bacchi and M. Castiglione</i>	2173
Interstitial pneumopathy after mantle field irradiation for Hodgkin's disease <i>H. Pape, A. Mulhern, J.v.d. Haar, I. Ernst, U. Göbel and G. Schmitt</i>	2177

Letters

Letters to the Editor: Comments on <i>The Role of Reproductive and Menstrual Factors in Cancer of the Breast Before and After Menopause</i> , Talamini <i>et al.</i> , <i>Eur J Cancer</i> , 32A, No. 2, pp. 303–310, 1996 (i) <i>L. Berstein</i> (ii) Response from: <i>S. Franceschi, R. Talamini and C. La Vecchia</i>	2181
p21 ^{WAF1} and p53 immunohistochemical expression in breast carcinoma may predict therapeutic response to adjuvant treatment <i>M. Barbareschi, C. Doglioni, S. Veronese, M. Bonzanini, P. Dalla Palma, A.L. Harris and O. Caffo</i>	2182
Is the time interval between diagnosis and radiation treatment an important factor in brain metastases? <i>I. Henríquez, C. Conill, E. Verger and F. Gaus</i>	2184
Malignant lymphoma with severe hypoglycaemia <i>C. Camci, S. Paydaş, B. Şahin and E. Coşar</i>	2185

NUMBER 13

International Cancer News		2187
Editorial		
	Chemotherapy of high-grade gliomas: beginning of a new era or the end of the old? <i>M. Brada and G. Sharpe</i>	2193
Current Controversies in Cancer		
	Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases? <i>Pro: A.M. Cohen and N.E. Kemeny</i> <i>Contra: C.-H. Köhne and J. Wils</i> <i>Arbiter: P.G. de Takats and D.J. Kerr</i>	2195
Point of View		
	Inheritance and susceptibility to tumours of the large bowel: a new classification of colorectal malignancies <i>M. Ponz de Leon, P. Benatti and L. Roncucci</i>	2206
Review		
	Intra-epithelial and invasive cervical neoplasia during HIV infection <i>M. Boccalon, U. Tirelli, F. Sopracordevole and E. Vaccher</i>	2212
Meeting Highlight		
	Sixth Charles Heidelberg Conference on "Control of Cell Proliferation and Differentiation: Molecular Targets in Carcinogenesis and Cancer Therapy", 9-13 July 1995, Essen, Germany <i>M.F. Rajewsky</i>	2218
Clinical Oncology		
	Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study <i>M. Sanson, A. Ameri, A. Monjour, T. Sahmoud, P. Ronchin, M. Poisson and J.Y. Delattre</i>	2229
	The Charing Cross Hospital experience with temozolomide in patients with gliomas <i>E.S. Newlands, S.M. O'Reilly, M.G. Glaser, M. Bower, H. Evans, C. Brock, M.H. Brampton, I. Colquhoun, P. Lewis, J.M. Rice-Edwards, R.D. Illingworth and P.G. Richards</i>	2236
	Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas <i>C. Hagel, G. Laking, R. Laas, S. Scheil, R. Jung, K. Milde-Langosch and D.K. Stavrrou</i>	2242

The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer <i>W.K. Evans and T. Le Chevalier</i>	2249
Unknown primary carcinoma: randomised studies are needed to identify optimal treatments and their benefits <i>D.C. Farrugia, A.R. Norman, M.C. Nicolson, M. Gore, E.O. Bolodeoku, A. Webb and D. Cunningham</i>	2256
Complications of an implantable venous access device (Port-a-Cath [®]) during intermittent continuous infusion of chemotherapy <i>R.L. Poorter, F.N. Lauw, W.A. Bemelman, P.J.M. Bakker, C.W. Taat and C.H.N. Veenhof</i>	2262
Surveillance versus adjuvant chemotherapy in stage I non-seminomatous testicular cancer: a decision analysis <i>A.M. Stiggelbout, G.M. Kiebert, J.C.J.M. de Haes, H.J. Keizer, G. Stoter, R. de Wit, J.B. Vermorken, J.W.H. Leer and J. Kievit</i>	2267
The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments <i>L.G. Walker, K.P. Wesnes, S.D. Heys, M.B. Walker, J. Lolley and O. Eremin</i>	2275
Quality of life: perception of lung cancer patients <i>A. Montazeri, R. Milroy, C.R. Gillis and J. McEwen</i>	2284

Paediatric Oncology

<i>Announcement</i>	New section—Paediatric Updates	2290
<i>Review</i>	Etoposide for the treatment of paediatric tumours: what is the best way to give it? <i>S.P. Lewis and D.R. Newell</i>	2291
	Screening for neuroblastoma in late infancy by use of EIA (enzyme-linked immunoassay) method: 115 000 screened infants in Austria <i>R. Kerbl, C.E. Urban, P.F. Ambros, H. Lackner, R. Ladenstein, E. Spuller, I. Mutz, I. Ambros, G. Amann, H. Gadner and L. Parker</i>	2298

Epidemiology and Cancer Prevention

Primary gastric non-Hodgkin's lymphoma stage IE and IIE <i>M.L.M. Lybeert, W. De Neve, L.W. Vrints, V. Coen and J.W.W. Coebergh</i>	2306
--	------

Experimental Oncology

Tumour necrosis factor and interferon are selectively cytostatic <i>in vitro</i> for hormone-dependent and hormone-independent human breast cancer cells <i>H. Mueller, N. Flury, R. Liu, S. Scheidegger and U. Eppenberger</i>	2312
--	------

Analysis of <i>O</i> ⁶ -methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction <i>J. Hansson, G. Martenhed, S. Egyházi, E. Tani and A. Platz</i>	2319
Cisplatin combined with the new cisplatin-procaine complex DPR: <i>in vitro</i> and <i>in vivo</i> studies <i>M. Viale, M.O. Vannozzi, F. Merlo, S. Cafaggi, B. Parodi and M. Esposito</i>	2327
Examination of multidrug resistance in cell lines and primary breast tumours by flow cytometry <i>I. Brotherick, B.K. Shenton, M. Egan, W.E. Cunliffe, D.A. Browell, L.G. Lunt, J.R. Young and M.J. Higgs</i>	2334
Enhanced invasiveness of tumour cells after host exposure to heavy metals <i>A. Haga, H. Nagase, H. Kito and T. Sato</i>	2342
Oestrogen and progesterone receptors in gastrointestinal cancer cell lines <i>E. Jacobs, S.A. Watson, J.D. Hardcastle and J.F.R. Robertson</i>	2348

Short Communications

A pilot study to evaluate paclitaxel (Taxol [®]) as primary medical treatment for patients with inoperable stage III and IV breast carcinoma <i>C.N. Rees, D. Sinnott, C. Lowdell, J. English and R.C. Coombes</i>	2354
Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy <i>D.C. Currow, M. Findlay, K. Cox and P.R. Harnett</i>	2357
Polymorphisms in <i>P21^{CIP1/WAF1}</i> are not correlated with <i>TP53</i> status in sporadic ovarian tumours <i>B.J. Milner, L. Hosking, S. Sun, N.E. Hailes and W.D. Foulkes</i>	2360

Letters

Letters to the Editor: Comments on <i>Prebiopsy Neo-adjuvant Endocrine Therapy for Breast Cancer to Prevent Post-surgery Trauma-induced Growth Factor and Immune-suppression Mediated Tumour Progression</i> , Oliver <i>et al.</i> , <i>Eur J Cancer</i> , 32A, No. 3, pp. 396–397, 1996 (i) <i>K. Mokbel</i> (ii) <i>Response from R.T.D. Oliver</i>	2364
A phase I/II trial of epirubicin and high dose tamoxifen as a potential modulator of multidrug resistance in advanced hepatocellular carcinoma <i>M. Raderer, J. Pidlich, C. Müller, F. Pfeffel, G.V. Kornek, M. Hejna and W. Scheithauer</i>	2366
Serum and urinary vascular endothelial growth factor levels in non-small cell lung cancer patients <i>G. Ferrari and G.V. Scagliotti</i>	2368
Abnormalities of the <i>P16^{INK4A}</i> gene in thyroid cancer cell lines <i>M. Ivan, D. Wynford-Thomas and C.J. Jones</i>	2369

	Lack of carboplatin activity in malignant lymphomas	2370
	<i>M. Balzarotti, C. Tondini, V. Bonfante, L. Devizzi, S. Viviani, M. Fornier and A. Santoro</i>	
	Radon exposure and incidence of paediatric malignancies	2371
	<i>R. Thorne, N.K. Foreman and M.G. Mott</i>	
	Very high male lung cancer incidence in areas with tobacco industries	2372
	<i>M.L.G. Janssen-Heijnen, J.W.W. Coebergh and J. van Reek</i>	
Correction and Apology		
	Mixing anthracyclines and radiotherapy in early breast cancer: how safe is it?	2374
	<i>P. HijiYiannakis and J.R. Yarnold</i>	
Calendar of Forthcoming Meetings		I

NUMBER 14

Special Issue: Basic and Clinical Research on Angiogenesis

Guest editors: G. Gasparini and J. Folkman

<i>Overview</i>	Angiogenesis research up to 1996. A commentary on the state of art and suggestions for future studies	2379
	<i>G. Gasparini</i>	
	Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models	2386
	<i>D. Hanahan, G. Christofori, P. Naik and J. Arbeit</i>	
	Tumour suppressor genes and angiogenesis: the role of <i>TP53</i> in fibroblasts	2394
	<i>V. Stellmach, O.V. Volpert, S.E. Crawford, J. Lawler, R.O. Hynes and N. Bouck</i>	
	Role of soluble mediators in angiogenesis	2401
	<i>F. Bussolino, A. Albini, G. Camussi, M. Presta, G. Viglietto, M. Ziche and G. Persico</i>	
	Vascular endothelial growth factor	2413
	<i>N. Ferrara</i>	
	Role of integrins in angiogenesis	2423
	<i>P.C. Brooks</i>	
	How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases	2430
	<i>P.J. Polverini</i>	

Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis <i>J. Rak, J. Filmus and R.S. Kerbel</i>	2438
Angiogenesis and metastasis <i>L.M. Ellis and I.J. Fidler</i>	2451
TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy <i>B.A. Teicher, Y. Emi, Y. Kakeji and D. Northey</i>	2461
Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor <i>Ke-Lin, Qu-Hong, J.A. Nagy, I.A. Eckelhoefer, E.M. Masse, A.M. Dvorak and H.F. Dvorak</i>	2467
Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation <i>P.B. Vermeulen, G. Gasparini, S.B. Fox, M. Toi, L. Martin, P. McCulloch, F. Pezzella, G. Viale, N. Weidner, A.L. Harris and L.Y. Dirix</i>	2474
Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies <i>G. Gasparini</i>	2485
Angiogenesis in primary lung cancer and lung secondaries <i>F. Pezzella, A. Di Bacco, S. Andreola, A.G. Nicholson, U. Pastorino and A.L. Harris</i>	2494
Prognostic value of angiogenesis in gastro-intestinal tumours <i>Y.S. Chung, K. Maeda and M. Sowa</i>	2501
Intratumoral vascularity as a prognostic factor in cancers of the urogenital tract <i>N. Weidner</i>	2506
Clinical significance of the determination of angiogenic factors <i>M. Toi, T. Taniguchi, Y. Yamamoto, T. Kurisaki, H. Suzuki and T. Tominaga</i>	2513
TNP-470 (AGM-1470): mechanisms of action and early clinical development <i>V. Castronovo and D. Belotti</i>	2520
Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer <i>D.C. Talbot and P.D. Brown</i>	2528
New perspectives in clinical oncology from angiogenesis research <i>J. Folkman</i>	2534
Information for Authors	I

SUPPLEMENT 1

Second Educational Convention of the European School of Oncology
Vienna, Austria Center, 27–29 June 1996

SUPPLEMENT 2

7th EORTC Breast Cancer Working Conference
Bordeaux, France, September 10–13 1996

SUPPLEMENT 3

Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation <i>D. Cunningham</i>	S1
Future directions for clinical research with CPT-11 (irinotecan) <i>D. Von Hoff</i>	S9
Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer <i>Y. Shimada, P. Rougier and H. Pitot</i>	S13
Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective <i>H. Bleiberg and E. Cvitkovic</i>	S18
CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer <i>L. Saltz, Y. Shimada and D. Khayat</i>	S24
Information for Authors	I

SUPPLEMENT 4

Current approaches in cytoprotection: the role of amifostine (Ethyol®) in altering and ameliorating toxicities in Cancer therapy <i>R.M. Bukowski</i>	S1
The need for cytoprotection <i>R.M. Bukowski</i>	S2
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol®) <i>R.L. Capizzi</i>	S5
WR-1065, the active metabolite of amifostine (Ethyol®), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells <i>D.S. Alberts, L.A. Speicher, M. Krutzsch, J. Wymer, R.L. Capizzi, J. Conlon, A. Barrett and M. Aickin</i>	S17
Cardioprotection of rat heart myocytes with amifostine (Ethyol®) and its free thiol, WR-1065, <i>in vitro</i> <i>R.T. Dorr, K. Lagel and S. McLean</i>	S21
Amifostine (Ethyol®): pharmacokinetic and pharmacodynamic effects <i>in vivo</i> <i>W.J.F. van der Vijgh and A.E.C. Korst</i>	S26

The potential role of amifostine (Ethyol [®]) in haematological malignancies <i>N.C. Gorin</i>	S31
Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol [®]) <i>L.M. Schuchter</i>	S40
Clinical effects of amifostine (Ethyol [®]) in patients treated with carboplatin <i>G.T. Budd, R. Ganapathi, R.M. Bukowski and S. Murthy</i>	S43
Amifostine (Ethyol [®]): dosing, administration and patient management guidelines <i>R.M. Bukowski</i>	S46

SUPPLEMENT 5

Introduction <i>P. Rougier</i>	S1
Colorectal cancer: the challenge <i>H. Bleiberg</i>	S2
Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies <i>R. Labianca, A. Pessi, G. Facendola, M. Pirovano and G. Luporini</i>	S7
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens <i>P. Ross, J. Heron and D. Cunningham</i>	S13
Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents <i>H.-J. Schmoll</i>	S18
A glimpse of the future. New directions in the treatment of colorectal cancer <i>E. Van Cutsem</i>	S23
A retrospective study of resource utilisation in the treatment of advanced colorectal cancer in Europe <i>K. Torfs and S. Pocceschi</i>	S28
<i>Reprinted Paper</i>	
‘Tomudex’ (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia <i>D. Cunningham, J.R. Zalcberg, U. Rath, I. Olver, E. Van Cutsem, C. Svensson, J.F. Seitz, P. Harper, D. Kerr, G. Perez-Manga, M. Azab, L. Seymour, K. Lowery and the ‘Tomudex’ Colorectal Cancer Study Group</i>	I
Information for Authors	XIII